Phathom Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
Phathom Pharmaceuticals, Inc. (PHAT), a Delaware corporation, filed this Current Report on Form 8-K on August 8, 2024. The filing serves to announce the company's financial results for the quarter ended June 30, 2024, via a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the referenced press release (Exhibit 99.1) and are not explicitly stated in the body of this 8-K document.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended June 30, 2024.
Guidance, Outlook, and Risks
The filing text does not include specific guidance, outlook, management commentary, risks, contingencies, or unusual items. The document notes that the information in this report, including the press release, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific Q2 2024 financial figures.
- Verify the company's cash runway and burn rate, as these are not detailed in the 8-K text.
- Confirm any updates to clinical trial progress or regulatory milestones mentioned in the full press release.
- Check for any forward-looking statements or revised guidance provided in the referenced exhibit.